Jeito Capital Archives | Be Korea-savvy
Jeito Capital Co-leads $156 Million Oversubscribed Series B financing in Quell Therapeutics

Jeito Capital Co-leads $156 Million Oversubscribed Series B financing in Quell Therapeutics

Paris, France, Nov. 29 (Korea Bizwire) – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led a $156 million oversubscribed Series B financing round in Quell Therapeutics (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by [...]

Jeito Capital Becomes a Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 Million ($630 Million)

Jeito Capital Becomes a Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 Million ($630 Million)

Paris, Sept. 20 (Korea Bizwire) – Jeito Capital, a rapidly growing, new, independent Private Equity firm dedicated to biotech and biopharma, today announced the final closing of its first fund, Jeito I, at €534 million ($630 million), exceeding its original target of €500 million. Jeito I is the largest European fund dedicated to supporting companies in [...]

Jeito Capital Becomes Key Investor in Alentis Therapeutics as Part of $67 Million Series B Financing Round

Jeito Capital Becomes Key Investor in Alentis Therapeutics as Part of $67 Million Series B Financing Round

Paris, France, June 15 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today announces that it has become a key investor as part of a $67 million Series B financing round in Alentis Therapeutics (Alentis). The Swiss biotech company, a spin-off of French Inserm with R&D in [...]

Jeito Capital Leads Oversubscribed $92 Million Series C Financing Round in Pulmocide

Jeito Capital Leads Oversubscribed $92 Million Series C Financing Round in Pulmocide

Paris, France, May 27 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today announces that it has led an oversubscribed $92million Series C financing round in Pulmocide, a late-stage biopharmaceutical company developing novel therapies for patients suffering from serious acute and chronic respiratory diseases. Jeito led [...]

Jeito Capital Leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and Leader in Rare Skeletal Disorders

Jeito Capital Leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and Leader in Rare Skeletal Disorders

Paris, France, Dec. 14 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has led a €20 million Series A financing in InnoSkel, a newly launched pioneering platform biotechnology company developing therapies for rare and life-threatening skeletal diseases. Jeito co-led the financing in a [...]

Sanofi Selects Jeito Capital as its First Investment into a Private French-based Fund

Sanofi Selects Jeito Capital as its First Investment into a Private French-based Fund

Paris, France, Nov. 13 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that Sanofi has made a €50 million investment in Jeito Capital. The investment will be deployed by Jeito’s highly experienced team of pharmaceutical and biotech experts in line with its investment criteria to provide [...]

Jeito Capital Becomes Major Investor in SparingVision as Part of €44.5 Million Financing

Jeito Capital Becomes Major Investor in SparingVision as Part of €44.5 Million Financing

Paris, France, Oct. 21 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has become a major investor in SparingVision, a French preclinical stage biotech company focused on gene therapy in ophthalmology. The €44.5 million financing round brought together new investors alongside Jeito including [...]

Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics

Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics

Paris, France, Sept. 14 (Korea Bizwire) – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that it has co-led a $110 million Series A financing in Neogene Therapeutics, Inc. (“Neogene”), a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer. [...]